NurExone Biologic Secures Master Cell Bank

A Key Milestone for Therapeutic Exosome ProductionTORONTO and HAIFA, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) ("NurExone" or the "Company"), a developer of exosome-based therapies for regenerative medicine, is pleased to announce that it has acquired a master cell bank from a U.S. manufacturer for an undisclosed amount (the “Acquisition”). The Acquisition marks a major step in ensuring a stable and scalable supply chain for production of ex ...